You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNialamide
Accession NumberDB04820
TypeSmall Molecule
GroupsWithdrawn
DescriptionWithdrawn from the Canadian, US, and UK markets in 1963 due to interactions with food products containing tyrosine.
Structure
Thumb
Synonyms
1-(2-(Benzylcarbamoyl)ethyl)-2-isonicotinoylhydrazine
1-[2-(Benzylcarbamoyl)ethyl]-2-isonicotinoylhydrazine
2-(2-(Benzylcarbamoyl)ethyl)hydrazide isonicotinic acid
2-(2-(Benzylcarbamoyl)ethyl)hydrazide, isonicotinic acid
2-(2-(Benzylcarbamyl)ethyl)hydrazide isonicotinic acid
2-[2-(Benzylcarbamoyl)ethyl]hydrazide isonicotinic acid
BEIH
Isonicitinic acid 2-[(2-benzylcarbamoyl)ethyl]hydrazide
Isonicotinic acid 2-((2-benzylcarbamoyl)ethyl)hydrazide
Isonicotinic acid, {2-[2-(benzylcarbamoyl)ethyl]hydrazide}
Isonicotinic acid, {2-[2-(benzylcarbamoylethyl]hydrazide}
Isonicotinic acid, 2-(2-(benzylcarbamoyl)ethyl)hydrazide
Isonicotinic acid, 2-[2- (benzylcarbamoyl)ethyl]hydrazide
Isonicotinic acid, 2-[2-(benzylcarbamoyl)ethyl]hydrazide
Isonicotinic acid, 2-[2-(benzylcarbamoylethyl]hydrazide
N-(2-(Benzylcarbamyl)ethylamino)isonicotinamide
N-Benzyl-3-(2-isonicotinoylhydrazino)propanamide
N-benzyl-beta-(isonicotinoylhydrazine)propionamide
N-benzyl-beta-(isonicotinylhydrazino)propionamide
N-isonicotinoyl-n'(beta-n-benzylcarboxamidoethyl)hydrazine
N-isonicotinyl hydrazide
Nialamida
Nialamidum
Pyridine-4-carboxylic 2-[2-(benzylcarbamoyl)ethyl]hydrazide
External Identifiers
  • Lopac-N-1392
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
DelmoneurinaNot Available
EsprilNot Available
IsalizinaNot Available
MygalNot Available
NF-xIIINot Available
NialamidNot Available
NiamidNot Available
NiamidalNot Available
NiamideNot Available
NiaquitilNot Available
NiazinNot Available
NovazidNot Available
NuredalNot Available
NyazinNot Available
NyezinNot Available
PsicodistenNot Available
SurgexNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIT2Q0RYM725
CAS number51-12-7
WeightAverage: 298.3397
Monoisotopic: 298.14297584
Chemical FormulaC16H18N4O2
InChI KeyInChIKey=NOIIUHRQUVNIDD-UHFFFAOYSA-N
InChI
InChI=1S/C16H18N4O2/c21-15(18-12-13-4-2-1-3-5-13)8-11-19-20-16(22)14-6-9-17-10-7-14/h1-7,9-10,19H,8,11-12H2,(H,18,21)(H,20,22)
IUPAC Name
N-benzyl-3-(pyridin-4-ylformohydrazido)propanamide
SMILES
O=C(CCNNC(=O)C1=CC=NC=C1)NCC1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as beta amino acids and derivatives. These are amino acids having a (-NH2) group attached to the beta carbon atom.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentBeta amino acids and derivatives
Alternative Parents
Substituents
  • Beta amino acid or derivatives
  • Pyridine carboxylic acid or derivatives
  • Phenylmethylamine
  • Benzylamine
  • Benzenoid
  • Pyridine
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Secondary carboxylic acid amide
  • Carboxylic acid hydrazide
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationNot Available
PharmacodynamicsNot Available
Mechanism of actionNialamide was one of the first MAOI (monoamine oxidase inhibitor) antidepressants. It is chemically related to iproniazide, another MAOI derived from isonicotinic acid. //
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9828
Blood Brain Barrier+0.9382
Caco-2 permeable-0.5586
P-glycoprotein substrateNon-substrate0.589
P-glycoprotein inhibitor IInhibitor0.5514
P-glycoprotein inhibitor IINon-inhibitor0.8207
Renal organic cation transporterNon-inhibitor0.6666
CYP450 2C9 substrateNon-substrate0.8668
CYP450 2D6 substrateNon-substrate0.7826
CYP450 3A4 substrateNon-substrate0.6434
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorInhibitor0.8818
CYP450 2D6 inhibitorInhibitor0.816
CYP450 2C19 inhibitorInhibitor0.8993
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7334
Ames testAMES toxic0.9107
CarcinogenicityNon-carcinogens0.7368
BiodegradationNot ready biodegradable0.9791
Rat acute toxicity2.2756 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7944
hERG inhibition (predictor II)Inhibitor0.5599
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point151.6 °CPhysProp
logP0.87HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0873 mg/mLALOGPS
logP0.65ALOGPS
logP0.39ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)13.65ChemAxon
pKa (Strongest Basic)3.41ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area83.12 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity93.91 m3·mol-1ChemAxon
Polarizability32.07 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.64 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General References
  1. Benady DR, Clein LJ, Pare CM: Intramuscular nialamide in intractable depression. Dis Nerv Syst. 1965 Dec;26(12):792-4. [PubMed:5321917 ]
  2. OULES J, CAZABON: [TREATMENT OF DEPRESSIVE STATES WITH INTRAVENOUS NIAMIDE]. Toulouse Med. 1964 Dec;65:1298-302. [PubMed:14272189 ]
  3. VAISBERG M, McGAHEE CL, RADINGER N, SAUNDERS JC: Nialamide for the treatment of anergy and depression. Dis Nerv Syst. 1959 Aug;20(Suppl):22-5. [PubMed:13840714 ]
External Links
ATC CodesN06AF02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineNialamide may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineNialamide may increase the hypertensive activities of 3,4-Methylenedioxymethamphetamine.
AcarboseNialamide may increase the hypoglycemic activities of Acarbose.
AcebutololNialamide may increase the hypotensive activities of Acebutolol.
AlbiglutideNialamide may increase the hypoglycemic activities of Albiglutide.
AliskirenNialamide may increase the hypotensive activities of Aliskiren.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Nialamide.
AlogliptinNialamide may increase the hypoglycemic activities of Alogliptin.
AlprenololNialamide may increase the hypotensive activities of Alprenolol.
AltretamineAltretamine may increase the orthostatic hypotensive activities of Nialamide.
AmbrisentanNialamide may increase the hypotensive activities of Ambrisentan.
AmineptineNialamide may increase the serotonergic activities of Amineptine.
AmitriptylineNialamide may increase the serotonergic activities of Amitriptyline.
AmlodipineNialamide may increase the hypotensive activities of Amlodipine.
AmoxapineNialamide may increase the serotonergic activities of Amoxapine.
AmphetamineNialamide may increase the hypertensive activities of Amphetamine.
ApomorphineThe metabolism of Apomorphine can be decreased when combined with Nialamide.
ApraclonidineThe risk or severity of adverse effects can be increased when Nialamide is combined with Apraclonidine.
ArbutamineThe risk or severity of adverse effects can be increased when Nialamide is combined with Arbutamine.
ArformoterolThe risk or severity of adverse effects can be increased when Nialamide is combined with Arformoterol.
AtenololNialamide may increase the hypotensive activities of Atenolol.
AtomoxetineNialamide may increase the central neurotoxic activities of Atomoxetine.
AtropineNialamide may increase the hypertensive activities of Atropine.
BambuterolThe risk or severity of adverse effects can be increased when Nialamide is combined with Bambuterol.
BenazeprilNialamide may increase the hypotensive activities of Benazepril.
BendroflumethiazideNialamide may increase the hypotensive activities of Bendroflumethiazide.
BenzphetamineNialamide may increase the hypertensive activities of Benzphetamine.
BepridilNialamide may increase the hypotensive activities of Bepridil.
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Nialamide.
BetaxololNialamide may increase the hypotensive activities of Betaxolol.
BethanidineNialamide may increase the hypotensive activities of Bethanidine.
BezafibrateThe risk or severity of adverse effects can be increased when Nialamide is combined with Bezafibrate.
BimatoprostNialamide may increase the hypotensive activities of Bimatoprost.
BisoprololNialamide may increase the hypotensive activities of Bisoprolol.
BosentanNialamide may increase the hypotensive activities of Bosentan.
BretyliumNialamide may increase the hypotensive activities of Bretylium.
BrimonidineThe risk or severity of adverse effects can be increased when Nialamide is combined with Brimonidine.
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Nialamide.
BupranololNialamide may increase the hypotensive activities of Bupranolol.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Nialamide.
BupropionNialamide may increase the hypertensive activities of Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Nialamide.
CabergolineThe metabolism of Cabergoline can be decreased when combined with Nialamide.
CanagliflozinNialamide may increase the hypoglycemic activities of Canagliflozin.
CandesartanNialamide may increase the hypotensive activities of Candesartan.
CandoxatrilNialamide may increase the hypotensive activities of Candoxatril.
CaptoprilNialamide may increase the hypotensive activities of Captopril.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Nialamide.
CarteololNialamide may increase the hypotensive activities of Carteolol.
CarvedilolNialamide may increase the hypotensive activities of Carvedilol.
CeliprololNialamide may increase the hypotensive activities of Celiprolol.
ChlorothiazideNialamide may increase the hypotensive activities of Chlorothiazide.
ChlorphentermineNialamide may increase the hypertensive activities of Chlorphentermine.
ChlorpropamideNialamide may increase the hypoglycemic activities of Chlorpropamide.
ChlorthalidoneNialamide may increase the hypotensive activities of Chlorthalidone.
CilazaprilNialamide may increase the hypotensive activities of Cilazapril.
CirazolineNialamide may increase the hypertensive activities of Cirazoline.
CitalopramNialamide may increase the serotonergic activities of Citalopram.
ClemastineNialamide may increase the anticholinergic activities of Clemastine.
ClenbuterolThe risk or severity of adverse effects can be increased when Nialamide is combined with Clenbuterol.
ClomipramineNialamide may increase the serotonergic activities of Clomipramine.
ClonidineNialamide may increase the hypotensive activities of Clonidine.
CryptenamineNialamide may increase the hypotensive activities of Cryptenamine.
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Nialamide.
CyclothiazideNialamide may increase the hypotensive activities of Cyclothiazide.
CyproheptadineNialamide may increase the anticholinergic activities of Cyproheptadine.
DapagliflozinNialamide may increase the hypoglycemic activities of Dapagliflozin.
DapoxetineNialamide may increase the serotonergic activities of Dapoxetine.
DebrisoquinNialamide may increase the hypotensive activities of Debrisoquin.
DeserpidineNialamide may increase the hypotensive activities of Deserpidine.
DesipramineNialamide may increase the serotonergic activities of Desipramine.
DesvenlafaxineNialamide may increase the serotonergic activities of Desvenlafaxine.
DexmethylphenidateNialamide may increase the hypertensive activities of Dexmethylphenidate.
DextroamphetamineNialamide may increase the hypertensive activities of Dextroamphetamine.
DextromethorphanNialamide may increase the serotonergic activities of Dextromethorphan.
DiazoxideNialamide may increase the hypotensive activities of Diazoxide.
DiethylpropionNialamide may increase the hypertensive activities of Diethylpropion.
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Nialamide.
DiltiazemNialamide may increase the hypotensive activities of Diltiazem.
DipivefrinThe risk or severity of adverse effects can be increased when Nialamide is combined with Dipivefrin.
DisopyramideNialamide may increase the hypoglycemic activities of Disopyramide.
DobutamineThe risk or severity of adverse effects can be increased when Nialamide is combined with Dobutamine.
DomperidoneThe risk or severity of adverse effects can be increased when Nialamide is combined with Domperidone.
DorzolamideNialamide may increase the hypotensive activities of Dorzolamide.
DosulepinNialamide may increase the serotonergic activities of Dosulepin.
DoxapramNialamide may increase the hypertensive activities of Doxapram.
DoxazosinNialamide may increase the hypotensive activities of Doxazosin.
DoxepinNialamide may increase the serotonergic activities of Doxepin.
DoxylamineNialamide may increase the anticholinergic activities of Doxylamine.
DroxidopaThe risk or severity of adverse effects can be increased when Nialamide is combined with Droxidopa.
DulaglutideNialamide may increase the hypoglycemic activities of Dulaglutide.
DuloxetineNialamide may increase the serotonergic activities of Duloxetine.
EfonidipineNialamide may increase the hypotensive activities of Efonidipine.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Nialamide.
EmpagliflozinNialamide may increase the hypoglycemic activities of Empagliflozin.
EnalaprilNialamide may increase the hypotensive activities of Enalapril.
EnalaprilatNialamide may increase the hypotensive activities of Enalaprilat.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Nialamide.
EphedraThe risk or severity of adverse effects can be increased when Nialamide is combined with Ephedra.
EpinephrineNialamide may increase the hypertensive activities of Epinephrine.
EpoprostenolNialamide may increase the hypotensive activities of Epoprostenol.
EprosartanNialamide may increase the hypotensive activities of Eprosartan.
ErgotamineNialamide may increase the hypertensive activities of Ergotamine.
EscitalopramNialamide may increase the serotonergic activities of Escitalopram.
EsmirtazapineNialamide may increase the serotonergic activities of Esmirtazapine.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Nialamide.
EtoperidoneNialamide may increase the serotonergic activities of Etoperidone.
ExenatideNialamide may increase the hypoglycemic activities of Exenatide.
FelodipineNialamide may increase the hypotensive activities of Felodipine.
FenfluramineNialamide may increase the serotonergic activities of Fenfluramine.
FenoldopamNialamide may increase the hypotensive activities of Fenoldopam.
FenoterolThe risk or severity of adverse effects can be increased when Nialamide is combined with Fenoterol.
FluoxetineNialamide may increase the serotonergic activities of Fluoxetine.
FluvoxamineNialamide may increase the serotonergic activities of Fluvoxamine.
FormoterolThe risk or severity of adverse effects can be increased when Nialamide is combined with Formoterol.
FosinoprilNialamide may increase the hypotensive activities of Fosinopril.
FrovatriptanThe metabolism of Frovatriptan can be decreased when combined with Nialamide.
GliclazideNialamide may increase the hypoglycemic activities of Gliclazide.
GlimepirideNialamide may increase the hypoglycemic activities of Glimepiride.
GlipizideNialamide may increase the hypoglycemic activities of Glipizide.
GlyburideNialamide may increase the hypoglycemic activities of Glyburide.
GuanabenzNialamide may increase the hypotensive activities of Guanabenz.
GuanadrelNialamide may increase the hypotensive activities of Guanadrel.
GuanethidineNialamide may increase the hypotensive activities of Guanethidine.
GuanfacineNialamide may increase the hypotensive activities of Guanfacine.
HexamethoniumNialamide may increase the hypotensive activities of Hexamethonium.
HydralazineNialamide may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideNialamide may increase the hypotensive activities of Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Nialamide is combined with Hydrocodone.
HydroflumethiazideNialamide may increase the hypotensive activities of Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Nialamide is combined with Hydromorphone.
Hydroxyamphetamine hydrobromideNialamide may increase the hypertensive activities of Hydroxyamphetamine hydrobromide.
ImipramineNialamide may increase the serotonergic activities of Imipramine.
IndacaterolThe risk or severity of adverse effects can be increased when Nialamide is combined with Indacaterol.
IndalpineNialamide may increase the serotonergic activities of Indalpine.
IndapamideNialamide may increase the hypotensive activities of Indapamide.
IndenololNialamide may increase the hypotensive activities of Indenolol.
IndoraminNialamide may increase the hypotensive activities of Indoramin.
Insulin AspartNialamide may increase the hypoglycemic activities of Insulin Aspart.
Insulin DetemirNialamide may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineNialamide may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisineNialamide may increase the hypoglycemic activities of Insulin Glulisine.
Insulin HumanNialamide may increase the hypoglycemic activities of Insulin Human.
Insulin LisproNialamide may increase the hypoglycemic activities of Insulin Lispro.
IrbesartanNialamide may increase the hypotensive activities of Irbesartan.
IsoetarineThe risk or severity of adverse effects can be increased when Nialamide is combined with Isoetarine.
IsomethepteneThe risk or severity of adverse effects can be increased when Nialamide is combined with Isometheptene.
IsoprenalineThe risk or severity of adverse effects can be increased when Nialamide is combined with Isoprenaline.
IsradipineNialamide may increase the hypotensive activities of Isradipine.
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Nialamide.
LabetalolNialamide may increase the hypotensive activities of Labetalol.
LacidipineNialamide may increase the hypotensive activities of Lacidipine.
LanreotideNialamide may increase the hypoglycemic activities of Lanreotide.
LatanoprostNialamide may increase the hypotensive activities of Latanoprost.
LercanidipineNialamide may increase the hypotensive activities of Lercanidipine.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Nialamide.
LevomilnacipranNialamide may increase the serotonergic activities of Levomilnacipran.
LevonordefrinNialamide may increase the hypertensive activities of Levonordefrin.
LinezolidThe risk or severity of adverse effects can be increased when Nialamide is combined with Linezolid.
LiraglutideNialamide may increase the hypoglycemic activities of Liraglutide.
LisdexamfetamineNialamide may increase the hypertensive activities of Lisdexamfetamine.
LisinoprilNialamide may increase the hypotensive activities of Lisinopril.
LisurideThe metabolism of Lisuride can be decreased when combined with Nialamide.
LithiumThe risk or severity of adverse effects can be increased when Nialamide is combined with Lithium.
LofexidineNialamide may increase the hypotensive activities of Lofexidine.
LosartanNialamide may increase the hypotensive activities of Losartan.
Lu AA21004Nialamide may increase the serotonergic activities of Lu AA21004.
MacitentanNialamide may increase the hypotensive activities of Macitentan.
ManidipineNialamide may increase the hypotensive activities of Manidipine.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Nialamide.
MecamylamineNialamide may increase the hypotensive activities of Mecamylamine.
MecaserminNialamide may increase the hypoglycemic activities of Mecasermin.
MephentermineNialamide may increase the hypertensive activities of Mephentermine.
MequitazineNialamide may increase the anticholinergic activities of Mequitazine.
MetaraminolNialamide may increase the hypertensive activities of Metaraminol.
MetforminNialamide may increase the hypoglycemic activities of Metformin.
MethadoneThe risk or severity of adverse effects can be increased when Nialamide is combined with Methadone.
MethamphetamineNialamide may increase the hypertensive activities of Methamphetamine.
MethoxamineNialamide may increase the hypertensive activities of Methoxamine.
MethyldopaThe risk or severity of adverse effects can be increased when Nialamide is combined with Methyldopa.
Methylene blueNialamide may increase the serotonergic activities of Methylene blue.
MethylphenidateNialamide may increase the hypertensive activities of Methylphenidate.
MetipranololNialamide may increase the hypotensive activities of Metipranolol.
MetolazoneNialamide may increase the hypotensive activities of Metolazone.
MetoprololNialamide may increase the hypotensive activities of Metoprolol.
MianserinNialamide may increase the neurotoxic activities of Mianserin.
MibefradilNialamide may increase the hypotensive activities of Mibefradil.
MidodrineNialamide may increase the hypertensive activities of Midodrine.
MifepristoneNialamide may increase the hypoglycemic activities of Mifepristone.
MiglitolNialamide may increase the hypoglycemic activities of Miglitol.
MilnacipranNialamide may increase the serotonergic activities of Milnacipran.
MinoxidilNialamide may increase the hypotensive activities of Minoxidil.
MirtazapineNialamide may increase the central neurotoxic activities of Mirtazapine.
MoclobemideThe risk or severity of adverse effects can be increased when Nialamide is combined with Moclobemide.
MoexiprilNialamide may increase the hypotensive activities of Moexipril.
MorphineThe risk or severity of adverse effects can be increased when Nialamide is combined with Morphine.
MoxonidineNialamide may increase the hypotensive activities of Moxonidine.
NadololNialamide may increase the hypotensive activities of Nadolol.
NaratriptanThe metabolism of Naratriptan can be decreased when combined with Nialamide.
NateglinideNialamide may increase the hypoglycemic activities of Nateglinide.
NebivololNialamide may increase the hypotensive activities of Nebivolol.
NicardipineNialamide may increase the hypotensive activities of Nicardipine.
NicorandilNialamide may increase the hypotensive activities of Nicorandil.
NiguldipineNialamide may increase the hypotensive activities of Niguldipine.
NilvadipineNialamide may increase the hypotensive activities of Nilvadipine.
NimodipineNialamide may increase the hypotensive activities of Nimodipine.
NisoldipineNialamide may increase the hypotensive activities of Nisoldipine.
NitrendipineNialamide may increase the hypotensive activities of Nitrendipine.
NitroprussideNialamide may increase the hypotensive activities of Nitroprusside.
NorepinephrineNialamide may increase the hypertensive activities of Norepinephrine.
NortriptylineNialamide may increase the serotonergic activities of Nortriptyline.
OctreotideNialamide may increase the hypoglycemic activities of Octreotide.
OlanzapineNialamide may increase the serotonergic activities of Olanzapine.
OlmesartanNialamide may increase the hypotensive activities of Olmesartan.
OlodaterolThe risk or severity of adverse effects can be increased when Nialamide is combined with Olodaterol.
OmapatrilatNialamide may increase the hypotensive activities of Omapatrilat.
OrciprenalineThe risk or severity of adverse effects can be increased when Nialamide is combined with Orciprenaline.
OxprenololNialamide may increase the hypotensive activities of Oxprenolol.
OxycodoneThe risk or severity of adverse effects can be increased when Nialamide is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Nialamide.
PargylineNialamide may increase the hypotensive activities of Pargyline.
ParoxetineNialamide may increase the serotonergic activities of Paroxetine.
PasireotideNialamide may increase the hypoglycemic activities of Pasireotide.
PenbutololNialamide may increase the hypotensive activities of Penbutolol.
PentamidineNialamide may increase the hypoglycemic activities of Pentamidine.
PentoliniumNialamide may increase the hypotensive activities of Pentolinium.
PergolideThe metabolism of Pergolide can be decreased when combined with Nialamide.
PerindoprilNialamide may increase the hypotensive activities of Perindopril.
PethidineNialamide may increase the serotonergic activities of Pethidine.
PhenoxybenzamineNialamide may increase the hypotensive activities of Phenoxybenzamine.
PhentermineNialamide may increase the hypertensive activities of Phentermine.
PhentolamineNialamide may increase the hypotensive activities of Phentolamine.
PhenylephrineNialamide may increase the hypertensive activities of Phenylephrine.
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Nialamide is combined with Phenylpropanolamine.
PholcodinePholcodine may increase the serotonergic activities of Nialamide.
PinacidilNialamide may increase the hypotensive activities of Pinacidil.
PindololNialamide may increase the hypotensive activities of Pindolol.
PioglitazoneNialamide may increase the hypoglycemic activities of Pioglitazone.
PirbuterolThe risk or severity of adverse effects can be increased when Nialamide is combined with Pirbuterol.
PizotifenNialamide may increase the anticholinergic activities of Pizotifen.
PolythiazideNialamide may increase the hypotensive activities of Polythiazide.
PramlintideNialamide may increase the hypoglycemic activities of Pramlintide.
PrazosinNialamide may increase the hypotensive activities of Prazosin.
ProcaterolThe risk or severity of adverse effects can be increased when Nialamide is combined with Procaterol.
PropranololNialamide may increase the hypotensive activities of Propranolol.
ProtriptylineNialamide may increase the serotonergic activities of Protriptyline.
PRX-00023The metabolism of PRX-00023 can be decreased when combined with Nialamide.
QuinaprilNialamide may increase the hypotensive activities of Quinapril.
QuinineNialamide may increase the hypoglycemic activities of Quinine.
RamiprilNialamide may increase the hypotensive activities of Ramipril.
RemikirenNialamide may increase the hypotensive activities of Remikiren.
RepaglinideNialamide may increase the hypoglycemic activities of Repaglinide.
RescinnamineNialamide may increase the hypotensive activities of Rescinnamine.
ReserpineNialamide may increase the hypotensive activities of Reserpine.
RiociguatNialamide may increase the hypotensive activities of Riociguat.
RitodrineThe risk or severity of adverse effects can be increased when Nialamide is combined with Ritodrine.
RizatriptanThe metabolism of Rizatriptan can be decreased when combined with Nialamide.
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Nialamide.
RosiglitazoneNialamide may increase the hypoglycemic activities of Rosiglitazone.
SalbutamolThe risk or severity of adverse effects can be increased when Nialamide is combined with Salbutamol.
SalmeterolThe risk or severity of adverse effects can be increased when Nialamide is combined with Salmeterol.
SaprisartanNialamide may increase the hypotensive activities of Saprisartan.
SaxagliptinNialamide may increase the hypoglycemic activities of Saxagliptin.
SelexipagNialamide may increase the hypotensive activities of Selexipag.
SertralineNialamide may increase the serotonergic activities of Sertraline.
SitagliptinNialamide may increase the hypoglycemic activities of Sitagliptin.
SitaxentanNialamide may increase the hypotensive activities of Sitaxentan.
SpiraprilNialamide may increase the hypotensive activities of Spirapril.
SulfadiazineNialamide may increase the hypoglycemic activities of Sulfadiazine.
SulfamethoxazoleNialamide may increase the hypoglycemic activities of Sulfamethoxazole.
SulfisoxazoleNialamide may increase the hypoglycemic activities of Sulfisoxazole.
SumatriptanThe metabolism of Sumatriptan can be decreased when combined with Nialamide.
SunitinibNialamide may increase the hypoglycemic activities of Sunitinib.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Nialamide.
TelmisartanNialamide may increase the hypotensive activities of Telmisartan.
TemocaprilNialamide may increase the hypotensive activities of Temocapril.
TerbutalineThe risk or severity of adverse effects can be increased when Nialamide is combined with Terbutaline.
TerlipressinNialamide may increase the hypotensive activities of Terlipressin.
Testosterone PropionateThe risk or severity of adverse effects can be increased when Testosterone Propionate is combined with Nialamide.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Nialamide.
TetryzolineNialamide may increase the hypertensive activities of Tetryzoline.
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Nialamide.
TianeptineNialamide may increase the serotonergic activities of Tianeptine.
TiboloneNialamide may increase the hypotensive activities of Tibolone.
TicrynafenNialamide may increase the hypotensive activities of Ticrynafen.
TimololNialamide may increase the hypotensive activities of Timolol.
TolazamideNialamide may increase the hypoglycemic activities of Tolazamide.
TolazolineNialamide may increase the hypotensive activities of Tolazoline.
TolbutamideNialamide may increase the hypoglycemic activities of Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Nialamide.
TorasemideNialamide may increase the hypotensive activities of Torasemide.
TramadolTramadol may increase the neuroexcitatory activities of Nialamide.
TrandolaprilNialamide may increase the hypotensive activities of Trandolapril.
TravoprostNialamide may increase the hypotensive activities of Travoprost.
TrazodoneNialamide may increase the serotonergic activities of Trazodone.
TreprostinilNialamide may increase the hypotensive activities of Treprostinil.
TrichlormethiazideNialamide may increase the hypotensive activities of Trichlormethiazide.
TrimazosinNialamide may increase the hypotensive activities of Trimazosin.
TrimethaphanNialamide may increase the hypotensive activities of Trimethaphan.
TrimipramineNialamide may increase the serotonergic activities of Trimipramine.
UnoprostoneNialamide may increase the hypotensive activities of Unoprostone.
ValsartanNialamide may increase the hypotensive activities of Valsartan.
VenlafaxineNialamide may increase the serotonergic activities of Venlafaxine.
VilanterolThe risk or severity of adverse effects can be increased when Nialamide is combined with Vilanterol.
VilazodoneNialamide may increase the serotonergic activities of Vilazodone.
VortioxetineNialamide may increase the serotonergic activities of Vortioxetine.
XylometazolineNialamide may increase the hypotensive activities of Xylometazoline.
ZimelidineNialamide may increase the serotonergic activities of Zimelidine.
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with Nialamide.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Primary amine oxidase activity
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOB preferentially degrades benzylamine and phenylethylamine.
Gene Name:
MAOB
Uniprot ID:
P27338
Molecular Weight:
58762.475 Da
References
  1. Hovevey-Sion D, Kopin IJ, Stull RW, Goldstein DS: Effects of monoamine oxidase inhibitors on levels of catechols and homovanillic acid in striatum and plasma. Neuropharmacology. 1989 Aug;28(8):791-7. [PubMed:2506486 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Serotonin binding
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOA preferentially oxidizes biogenic amines such as 5-hydroxytryptamine (5-HT), norepinephrine and epinephrine.
Gene Name:
MAOA
Uniprot ID:
P21397
Molecular Weight:
59681.27 Da
References
  1. Hovevey-Sion D, Kopin IJ, Stull RW, Goldstein DS: Effects of monoamine oxidase inhibitors on levels of catechols and homovanillic acid in striatum and plasma. Neuropharmacology. 1989 Aug;28(8):791-7. [PubMed:2506486 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
O-methyltransferase activity
Specific Function:
Catalyzes the O-methylation, and thereby the inactivation, of catecholamine neurotransmitters and catechol hormones. Also shortens the biological half-lives of certain neuroactive drugs, like L-DOPA, alpha-methyl DOPA and isoproterenol.
Gene Name:
COMT
Uniprot ID:
P21964
Molecular Weight:
30036.77 Da
References
  1. Parvez S, Parvez SH, Youdim MB: Variation in activity of monoamine metabolizing enzymes in rat liver during pregnancy. Br J Pharmacol. 1975 Feb;53(2):241-6. [PubMed:1170911 ]
Comments
comments powered by Disqus
Drug created on September 11, 2007 14:20 / Updated on August 17, 2016 12:24